



# Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma

#### Citation

Siegel, D. S., P. Richardson, M. Dimopoulos, P. Moreau, C. Mitsiades, D. Weber, J. Houp, et al. 2014. "Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma." Blood Cancer Journal 4 (4): e202. doi:10.1038/bcj.2014.23. http://dx.doi.org/10.1038/bcj.2014.23.

#### **Published Version**

doi:10.1038/bcj.2014.23

#### Permanent link

http://nrs.harvard.edu/urn-3:HUL.InstRepos:12153006


#### Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

### **Share Your Story**

The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

**Accessibility** 





#### **CORRIGENDUM**

## Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma

DS Siegel<sup>1,9,10</sup>, P Richardson<sup>2,9</sup>, M Dimopoulos<sup>3</sup>, P Moreau<sup>4</sup>, C Mitsiades<sup>1</sup>, D Weber<sup>5</sup>, J Houp<sup>6</sup>, C Gause<sup>6</sup>, S Vuocolo<sup>6</sup>, J Eid<sup>6</sup>, T Graef<sup>7</sup> and KC Anderson<sup>8</sup>

Blood Cancer Journal (2014) 4, e202; doi:10.1038/bcj.2014.23; published online 11 April 2014

**Correction to:** *Blood Cancer Journal* (2014) **4,** e182; doi:10.1038/bcj.2014.1; published online 21 February 2014

Since the publication of this article, the authors have identified an error concerning one of the author affiliation addresses. KC Anderson was incorrectly affiliated to the following address: 'Merck & Co. Inc., Whitehouse Station, NJ, USA'. The correct address details are shown here.

The article has also been rectified, and now carries the correct information.

The Authors would like to apologise for any inconvenience this may have caused.

<sup>&</sup>lt;sup>1</sup>Myeloma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA; <sup>2</sup>Dana-Farber Cancer Institute, Boston, MA, USA; <sup>3</sup>Department of Clinical Therapeutics, University of Athens, Athens, Greece; <sup>4</sup>University Hospital, Nantes, France; <sup>5</sup>MD Anderson Cancer Center, Houston, TX, USA; <sup>6</sup>Merck & Co. Inc., Whitehouse Station, NJ, USA; <sup>7</sup>Pharmacyclics Inc., Sunnyvale, CA, USA and <sup>8</sup>Department of Medicine, Harvard Medical School and Kraft Family Blood Center, Dana-Farber Cancer Institute, Boston, MA, USA. Correspondence: Dr DS Siegel, Myeloma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA. E-mail: DSiegel@HackensackUMC.org

<sup>&</sup>lt;sup>9</sup>These authors contributed equally to this work.

<sup>&</sup>lt;sup>10</sup>As corresponding author, Dr Siegel assumes full responsibility for the overall content and integrity of the manuscript.